Human IL-36RA production in Escherichia coli with coexpression of E. coli methionine aminopeptidase. I. Comparison of IL-36RA production in different strains

Standard

Human IL-36RA production in Escherichia coli with coexpression of E. coli methionine aminopeptidase. I. Comparison of IL-36RA production in different strains. / Kolobov, A. A.; Kondratyeva, E. V.; Kudling, T. V.; Karasev, M. M.; Kalinin, R. S.; Khizhina, A. A.; Nimiritsky, P. P.; Stefanov, V. E.; Petrov, A. V.

In: Cell and Tissue Biology, Vol. 11, No. 6, 01.11.2017, p. 447-452.

Research output: Contribution to journal › Article › peer-review

Author

Kolobov, A. A. ; Kondratyeva, E. V. ; Kudling, T. V. ; Karasev, M. M. ; Kalinin, R. S. ; Khizhina, A. A. ; Nimiritsky, P. P. ; Stefanov, V. E. ; Petrov, A. V. / Human IL-36RA production in Escherichia coli with coexpression of E. coli methionine aminopeptidase. I. Comparison of IL-36RA production in different strains. In: Cell and Tissue Biology. 2017 ; Vol. 11, No. 6. pp. 447-452.

BibTeX

@article{6be4a1db4c31450da3173e5c47eb0fbf,

title = "Human IL-36RA production in Escherichia coli with coexpression of E. coli methionine aminopeptidase. I. Comparison of IL-36RA production in different strains",

abstract = "Generalized pustular psoriasis (GPP) is a rare, sometimes lethal, form of psoriasis caused by series of mutations in the interleukin-36 receptor antagonist (IL-36RA) gene associated with its reduced expression or activity. Administration of exogenous IL-36RA can be a potent therapeutic approach to treating GPP and other forms of psoriasis. Since cleavage of the starting N-formylmethionine residue from the N-terminal end is needed for full biological activity of IL-36RA, we have developed a technique for producing IL-36RA lacking N-formylmethionine residue in E. coli. We have created a series of plasmids carrying the E. coli methionine aminopeptidase (MAP) gene under the control of different promoters for coexpression of IL-36RA and MAP and tested their effect on IL-36RA production. The highest production of IL-36RA with <3% of unprocessed molecules with uncleaved N-terminal formylmethionine residue has been shown for E. coli strain carrying the MAP gene under the control of arabinose-inducible promoter.",

keywords = "coexpression, Interleukin, interleukin-36 receptor antagonist (IL-36RA), methionine, methionine aminopeptidase (MAP), recombinant protein",

author = "Kolobov, {A. A.} and Kondratyeva, {E. V.} and Kudling, {T. V.} and Karasev, {M. M.} and Kalinin, {R. S.} and Khizhina, {A. A.} and Nimiritsky, {P. P.} and Stefanov, {V. E.} and Petrov, {A. V.}",

note = "Publisher Copyright: {\textcopyright} 2017, Pleiades Publishing, Ltd.",

year = "2017",

month = nov,

day = "1",

doi = "10.1134/S1990519X17060062",

language = "English",

volume = "11",

pages = "447--452",

journal = "Cell and Tissue Biology",

issn = "1990-519X",

publisher = "МАИК {"}Наука/Интерпериодика{"}",

number = "6",

}

RIS

TY - JOUR

T1 - Human IL-36RA production in Escherichia coli with coexpression of E. coli methionine aminopeptidase. I. Comparison of IL-36RA production in different strains

AU - Kolobov, A. A.

AU - Kondratyeva, E. V.

AU - Kudling, T. V.

AU - Karasev, M. M.

AU - Kalinin, R. S.

AU - Khizhina, A. A.

AU - Nimiritsky, P. P.

AU - Stefanov, V. E.

AU - Petrov, A. V.

PY - 2017/11/1

Y1 - 2017/11/1

N2 - Generalized pustular psoriasis (GPP) is a rare, sometimes lethal, form of psoriasis caused by series of mutations in the interleukin-36 receptor antagonist (IL-36RA) gene associated with its reduced expression or activity. Administration of exogenous IL-36RA can be a potent therapeutic approach to treating GPP and other forms of psoriasis. Since cleavage of the starting N-formylmethionine residue from the N-terminal end is needed for full biological activity of IL-36RA, we have developed a technique for producing IL-36RA lacking N-formylmethionine residue in E. coli. We have created a series of plasmids carrying the E. coli methionine aminopeptidase (MAP) gene under the control of different promoters for coexpression of IL-36RA and MAP and tested their effect on IL-36RA production. The highest production of IL-36RA with <3% of unprocessed molecules with uncleaved N-terminal formylmethionine residue has been shown for E. coli strain carrying the MAP gene under the control of arabinose-inducible promoter.

AB - Generalized pustular psoriasis (GPP) is a rare, sometimes lethal, form of psoriasis caused by series of mutations in the interleukin-36 receptor antagonist (IL-36RA) gene associated with its reduced expression or activity. Administration of exogenous IL-36RA can be a potent therapeutic approach to treating GPP and other forms of psoriasis. Since cleavage of the starting N-formylmethionine residue from the N-terminal end is needed for full biological activity of IL-36RA, we have developed a technique for producing IL-36RA lacking N-formylmethionine residue in E. coli. We have created a series of plasmids carrying the E. coli methionine aminopeptidase (MAP) gene under the control of different promoters for coexpression of IL-36RA and MAP and tested their effect on IL-36RA production. The highest production of IL-36RA with <3% of unprocessed molecules with uncleaved N-terminal formylmethionine residue has been shown for E. coli strain carrying the MAP gene under the control of arabinose-inducible promoter.

KW - coexpression

KW - Interleukin

KW - interleukin-36 receptor antagonist (IL-36RA)

KW - methionine

KW - methionine aminopeptidase (MAP)

KW - recombinant protein

UR - http://www.scopus.com/inward/record.url?scp=85038245597&partnerID=8YFLogxK

U2 - 10.1134/S1990519X17060062

DO - 10.1134/S1990519X17060062

M3 - Article

AN - SCOPUS:85038245597

VL - 11

SP - 447

EP - 452

JO - Cell and Tissue Biology

JF - Cell and Tissue Biology

SN - 1990-519X

IS - 6

ER -

ID: 89864635